{
    "id": "3487033c-7c62-4034-8718-73a7c49b26a0",
    "indications": {
        "text": "carefully consider potential benefits risks diclofenac sodium delayed-release tablets treatment options deciding diclofenac sodium delayed-release tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ; gastrointestinal bleeding , ulceration , perforation ) . diclofenac sodium delayed-release tablets indicated : relief signs symptoms osteoarthritis relief signs symptoms rheumatoid arthritis acute long-term relief signs symptoms ankylosing spondylitis",
        "doid_entities": [
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "carefully consider potential benefits risks diclofenac sodium delayed-release tablets treatment options deciding diclofenac sodium delayed-release tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ; gastrointestinal bleeding , ulceration , perforation ) . observing response initial therapy diclofenac sodium delayed-release tablets , dose frequency adjusted suit individual patient \u2019 needs . relief osteoarthritis , recommended 100 150 mg/day divided doses ( 50 mg twice day three times day , 75 mg twice day ) . relief rheumatoid arthritis , recommended 150 200 mg/day divided doses ( 50 mg three times day . four times day , 75 mg twice day . ) . relief ankylosing spondylitis , recommended 100 125 mg/day , administered 25 mg four times day , extra 25 mg dose bedtime necessary . different formulations diclofenac [ ( diclofenac sodium enteric-coated tablets ) ; diclofenac sodium extended-release tablets ; diclofenac potassium immediate-release tablets ) ] necessarily bioequivalent even milligram strength .",
        "doid_entities": [
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "diclofenac sodium delayed-release tablets , usp available containing 50 mg 75 mg diclofenac sodium , usp . 50 mg tablets light brown , round , biconvex , enteric coated tablet imprinted \u201c d50 \u201d black ink one side plain side . available follows : bottles 60 ndc 59651-842-60 bottles 100 ndc 59651-842-01 bottles 1,000 ndc 59651-842-99 75 mg tablets pale pink , round , biconvex , enteric coated tablet imprinted \u201c d75 \u201d black ink one side plain side . available follows : bottles 60 ndc 59651-843-60 bottles 100 ndc 59651-843-01 bottles 500 ndc 59651-843-05 bottles 1,000 ndc 59651-843-99 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature . ] protect moisture . dispense tight , light-resistant container described usp using child-resistant closure . dispense medication guide available : www.aurobindousa.com/medication-guides . distributed : aurobindo pharma usa , inc. 279 princeton-hightstown road east windsor , nj 08520 manufactured : aurobindo pharma limited hyderabad-500 032 , india revised : 01/2025",
    "adverseReactions": "diclofenac sodium delayed-release tablets contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) diclofenac components product ( ; anaphylactic , serious skin ) . history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients ( ; anaphylactic reaction , exacerbation asthma related aspirin sensitivity ) . setting coronary artery bypass graft ( cabg ) surgery ( ; cardiovascular thrombotic events ) .",
    "ingredients": [
        {
            "name": "DICLOFENAC SODIUM",
            "code": "QTG126297Q",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4509"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "FD&C YELLOW NO. 6 ALUMINUM LAKE",
            "code": "GYP6Z2JR6Q"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "DIMETHICONE, UNSPECIFIED",
            "code": "92RU3N3Y1O",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11074"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FD&C BLUE NO. 2 ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "HYPROMELLOSE 2910 (50 MPA.S)",
            "code": "1IVH67816N",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "POLYETHYLENE GLYCOL 4000",
            "code": "4R4HFI6D95",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "FD&C RED NO. 40 ALUMINUM LAKE",
            "code": "6T47AS764T"
        }
    ],
    "organization": "Aurobindo Pharma Limited",
    "name": "DICLOFENAC SODIUM",
    "effectiveTime": "20250509",
    "indications_original": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation).\n                  \n                  Diclofenac sodium delayed-release tablets are indicated:\n                  \n                  \n                     for relief of the signs and symptoms of osteoarthritis\n                     for relief of the signs and symptoms of rheumatoid arthritis\n                     for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis",
    "contraindications_original": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation).\n                  \n                  After observing the response to initial therapy with diclofenac sodium delayed-release tablets, the dose and frequency should be adjusted to suit an individual patient\u2019s needs.\n                  \n                  For the relief of osteoarthritis, the recommended dosage is 100 to 150 mg/day in divided doses (50 mg twice a day or three times a day, or 75 mg twice a day).\n                  \n                  For the relief of rheumatoid arthritis, the recommended dosage is 150 to 200 mg/day in divided doses (50 mg three times a day. or four times a day, or 75 mg twice a day.).\n                  \n                  For the relief of ankylosing spondylitis, the recommended dosage is 100 to 125 mg/day, administered as 25 mg four times a day, with an extra 25 mg dose at bedtime if necessary.\n                  \n                  Different formulations of diclofenac [(diclofenac sodium enteric-coated tablets); diclofenac sodium extended-release tablets; diclofenac potassium immediate-release tablets)] are not necessarily bioequivalent even if the milligram strength is the same.",
    "warningsAndPrecautions_original": "Diclofenac Sodium Delayed-Release Tablets, USP are available containing 50 mg or 75 mg of diclofenac sodium, USP.\n                  \n                  The 50 mg tablets are light brown, round, biconvex, enteric coated tablet imprinted\u00a0\u201cD50\u201d in black ink on one side and plain on other side. They are available as follows:\n                  \n                  Bottles of 60\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 59651-842-60\n                  Bottles of 100\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 59651-842-01\n                  Bottles of 1,000\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 59651-842-99\n                  \n                  The 75 mg tablets are pale pink, round, biconvex, enteric coated tablet imprinted\u00a0\u201cD75\u201d in black ink on one side and plain on other side. They are available as follows: \n                  Bottles of 60\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 59651-843-60\n                  Bottles of 100\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 59651-843-01\n                  Bottles of 500\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 59651-843-05\n                  Bottles of 1,000\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 59651-843-99\n                  \n                  \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] \n                     \n                  \n                  \n                     \n                  \n                  \n                     Protect from moisture.\n                  \n                  Dispense in a tight, light-resistant container as described in the USP using a child-resistant closure.\n                     \n                         Dispense with Medication Guide available at: www.aurobindousa.com/medication-guides.\n                        \n                     \n                      Distributed by:\n                     Aurobindo Pharma USA, Inc.\n                     279 Princeton-Hightstown Road East Windsor, NJ 08520\n                      Manufactured by:\n                     Aurobindo Pharma Limited\n                     Hyderabad-500 032, India\n                      Revised: 01/2025",
    "adverseReactions_original": "Diclofenac sodium delayed-release tablets are contraindicated in the following patients: \n                  \n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see WARNINGS; Anaphylactic Reactions, Serious Skin Reactions). \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (see WARNINGS; Anaphylactic Reaction, Exacerbation of Asthma Related to Aspirin Sensitivity). \n                     In the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS;  Cardiovascular Thrombotic Events).",
    "drug": [
        {
            "name": "DICLOFENAC SODIUM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4509"
        }
    ]
}